Licofelone - Dual COX/LOX Inhibitor - Drug Development Information
Licofelone (ML3000) is a dual COX/LOX inhibitor currently under evaluation as a treatment for osteoarthritis. Licofelone is the first member of this new class of analgesic and anti-inflammatory drugs. Although phase III trials have been successfully completed, no dates for regulatory submission have been given.
- A - Z: Analgesic Drugs
- A - Z: Arthritis Drugs
- A - Z: Drug Costs
- A - Z: NSAIDs
- COX-2 Selective Inhibitors
- Inflammation
- Joint Pain
- Osteoarthritis
- Pain Relief
New NSAID Easier to Stomach
Licofelone, an experimental analgesic, causes less gastrointestinal (GI) adverse reactions than naproxen, according to a study involving healthy volunteers. Both are considered to be nonsteroidal anti-inflammatory drugs (NSAIDs), a group of drugs known for the potential to cause GI problems, from Arthritis Foundation.
Licofelone Research Website
Licofelone research website provides comprehensive, clinical information on the development of licofelone for the treatment of osteoarthritis. Licofelone is a new approach to the treatment of osteoarthritis. As a LOX/COX inhibitor, it balances the inhibition of these enzymes in the inflammatory pathway. Research is evaluating the benefits offered by this balanced approach to inhibition.
Licofelone - Analgesic and Anti-Inflammatory for Osteoarthritis
Clinical studies that have compared licofelone with conventional NSAIDs and COX-2 specific inhibitors suggest that it is at least as effective as these agents in providing symptomatic relief from OA but generally better tolerated, from drugdevelopment-technology.
ACR: Licofelone Offers Equal Efficacy With Better Tolerability
Licofelone is as effective as celecoxib for symptomatic osteoarthritis of the knee and shows both greater tolerability and a lower incidence of adverse events, researchers report, from PSLGroup.
